Fosaprepitant DimeglumineThird Party Manufacturing in India

Fosaprepitant dimeglumine is a prodrug, which means it is inactive when first administered and must be converted by the body into its active form. Once injected, fosaprepitant is rapidly transformed into aprepitant, the pharmacologically active molecule. Aprepitant works by blocking a specific receptor in the brain called the neurokinin-1 or NK1 receptor. This receptor is normally activated by a neurotransmitter called substance P, which plays a major role in triggering the vomiting reflex, especially during the delayed phase of chemotherapy-induced nausea and vomiting. By occupying the NK1 receptor, aprepitant prevents substance P from binding and sending the signal that leads to nausea and vomiting. Importantly, aprepitant works through a completely different pathway than other antiemetic drugs that target serotonin or dopamine receptors, which is why it is so effective when used alongside them. The drug crosses the blood-brain barrier and acts directly on the brain's vomiting center in the area postrema. When fosaprepitant is given together with a serotonin receptor antagonist like ondansetron and a corticosteroid like dexamethasone, all three major pathways of the vomiting reflex are blocked at the same time. This triple combination provides superior protection against both the immediate and delayed nausea caused by highly emetogenic chemotherapy, particularly cisplatin-based regimens.

Therapeutic Uses

Fosaprepitant Dimeglumine is prescribed for the prevention of:

• Chemotherapy-Induced Nausea and Vomiting (CINV): Indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, in both adults and pediatric patients 6 months and older.
• Moderately Emetogenic Chemotherapy (MEC): Used for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.
• Postoperative Nausea and Vomiting (PONV): May be used as part of a multimodal approach for the prevention of postoperative nausea and vomiting in surgical settings.

Why Manufacturers Choose Fosaprepitant Dimeglumine

Fosaprepitant dimeglumine is the intravenous prodrug form of aprepitant, one of the most important innovations in antiemetic therapy over the past two decades. As an NK1 receptor antagonist, it fills a critical gap in chemotherapy supportive care that serotonin antagonists alone could not address. The growing number of cancer patients worldwide receiving highly emetogenic chemotherapy drives consistent demand for this drug. Indian manufacturers with lyophilization capabilities can produce this high-value injectable for both domestic and export markets, including WHO-GMP regulated markets. This makes Fosaprepitant Dimeglumine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.